Derma Roller Hair Growth: What the Trials Actually Used

Does a derma roller help hair grow?

Possibly, as an add-on to minoxidil, but the evidence for it does not describe a home roller. The two best-known positive trials used a 1.5 mm roller applied by clinicians, weekly or fortnightly, until the scalp reddened or bled at pinpoints. The largest trial covered here, 245 women in 2026, found scheduled microneedling at about 0.5 mm added nothing to minoxidil after 24 weeks. In the US, microneedling devices are regulated for aesthetic use, and the category was created for facial acne scars, not hair loss.

Derma roller hair treatment is usually sold as an inexpensive home kit: a handle with a drum of fine needles that you roll over the scalp, usually alongside minoxidil. The case for it rests on a handful of trials, and one statistic from them is quoted more than any other: 82% of men rated themselves more than 50% improved, against 4.5% on minoxidil alone.

That number is real. But the device that produced it was not a home roller, the person holding it was not the patient, and the 82% was the men's own rating of their hair. This page goes through each trial and what it actually tested, then covers the side effects, including three case reports from 2026, and where needling sits next to the two drugs with the strongest evidence. If you are not yet sure what kind of hair loss you have, the Norwood stage finder is a better first step than any device.

What the derma roller hair studies actually tested

Every trial below delivered the needling as scheduled treatment sessions rather than home use, and none used a sham procedure. The comparison was needling, with or without a drug, against a drug alone (or, in one trial, PRP), so patients knew which group they were in.

Study	Who	Device and depth	Schedule	Compared with	Result
Dhurat 2013 (Int J Trichology)	100 men, Norwood 3 vertex or 4	Derma roller, 1.5 mm, in clinic, to "mild erythema"	Weekly for 12 weeks	5% minoxidil alone	Hair count +91.4 vs +22.2; 82% vs 4.5% rated themselves >50% improved
Kumar 2018 (J Cutan Aesthet Surg)	68 men, Norwood 3 and 4	Derma roller, 1.5 mm, in clinic, to "pinpoint bleeding"	Weekly × 4, then fortnightly × 4	5% minoxidil alone	+12.52 vs +1.89 hairs per square inch; 4 men reported 50% improvement vs none
Bao 2022 (J Dermatolog Treat)	71 men	Electric microneedling device	Every 3 weeks, 8 sessions	Minoxidil alone; needling alone	Combination beat either single treatment
Adistri 2024 (Dermatol Reports)	36 men, Norwood 3 to 6	0.6 mm needling to pinpoint bleeding or mild erythema (device type not named)	Every 4 weeks, 12 weeks	5% minoxidil alone	Density gain 95.6 vs 52.4 hairs/cm²
Leonik 2024 (Postepy Dermatol Alergol)	92 men	1.0 mm needling to pinpoint bleeding (device type not named)	3 sessions, a month apart	Needling alone; needling plus minoxidil; PRP	All groups gained count and density, with no significant difference between groups; only PRP thickened hair
Liu 2026 (J Am Acad Dermatol)	245 women, mild to moderate	36-needle cartridge, 500 to 550 µm, single centre	Every 2 or 4 weeks, 24 weeks	2% minoxidil alone	No difference on any measure

Three things stand out once the rows are side by side.

The two best-known positive trials used a deep roller and a clinical endpoint. Dhurat's team shaved the scalp, cleaned it with povidone-iodine, and rolled in three directions until the skin reddened. Kumar's team went on until they saw pinpoint bleeding. Both told patients to skip minoxidil on the day of the procedure and wait 24 hours after it. That is a controlled, antiseptic procedure, done by someone who can see the endpoint.

The largest trial is also the most recent, and it found nothing. Liu et al randomised 245 women and 234 completed. All three groups gained hair, and needling every two or four weeks did not add to 2% minoxidil on the primary endpoint or any secondary one. The authors concluded that microneedling at 500 to 550 µm "did not provide additional clinical benefit over 2% topical minoxidil alone after 24 weeks." The caveats are real. The trial was in women, used the 2% strength, was open-label and used a 36-needle cartridge device rather than a roller. But its depth, about 0.5 mm, is in the range sold for home use, and it was delivered as a scheduled procedure at a single centre.

Microneedling alone has very little evidence. Only two of these trials had a needling-only arm, and they point in different directions. Bao's needling-alone group did worse than the combination, while in Leonik's trial needling alone and needling plus minoxidil gained similar amounts, with no significant difference between any of the groups. Neither trial had an untreated control. A 2024 meta-analysis that pooled both kinds of comparison concluded that the effect of microneedling alone "may be limited" (Xu et al, Chin Med Nat Prod 2024, in the next section), which is why almost every regimen online pairs the roller with minoxidil.

The 82% figure, and why a near-copy of the trial got 13%

The 82% is a self-assessment, not a hair count. In the 2013 trial, 41 of 50 men who were needled rated their improvement at over 50%, against 2 of 44 on minoxidil alone (Dhurat et al, Int J Trichology 2013, linked in the table above). The men knew whether they were being needled every week. A rating like this is the endpoint most exposed to expectation.

The objective numbers from that trial are more useful, and they have their own oddity. The minoxidil-only group gained 22.2 hairs in the marked patch over 12 weeks, and the combined group 91.4. The paper's own discussion notes that minoxidil and finasteride produce a small percentage of new growth "after at least 4 months of daily usage", so a 12-week trial ended before minoxidil alone would be expected to show much. Twelve weeks favours whatever works fastest.

Five years later, Kumar et al ran almost the same design in 68 men, with the same 1.5 mm roller, the same twice-daily 5% minoxidil and the same 12 weeks (J Cutan Aesthet Surg 2018). The combination still won on hair count. But 4 men in the needling group reported 50% improvement, the highest rating anyone in that trial gave, not 41 men above 50%, and the authors' conclusion includes a sentence that rarely gets quoted: the response "was not cosmetically significant."

Two trials, nearly the same protocol, 82% and 13% (4 of the 31 men who completed the needling arm, rating 50% rather than over 50%). The difference between them is a better guide to derma roller hair expectations than either number alone.

What the meta-analyses add up to

Pooled, needling plus minoxidil beats minoxidil alone on hair count, but the trials disagree with each other a lot and none of them is blinded to the patient. Three recent meta-analyses cover overlapping sets of trials, and they do not agree on hair thickness.

Meta-analysis	Trials, people	Hair count or density	Hair thickness	Other findings
Pei et al, J Cosmet Dermatol 2024	13 RCTs, 696	Density better with combination than needling or a drug alone	Better with combination	Doctors rated the combination higher; patient satisfaction difference not significant (RR 3.44, 95% CI 0.67 to 17.59)
Xu et al, Chin Med Nat Prod 2024	8 RCTs, 472	Better with combination	No pooled difference (SMD −0.21, 95% CI −2.94 to 2.52)	Needling alone "may be limited"; authors favoured depths under 1 mm
Ahmed et al, Arch Dermatol Res 2025	12 RCTs, 631	SMD 1.32 (95% CI 0.73 to 1.92), I² = 88%	SMD 0.34 (0.11 to 0.58), I² = 0%	More adverse events with needling: 74 vs 59

An I² of 88% means the individual trials gave very different answers, so the pooled effect is an average of results that do not agree. Ahmed's subgroup analysis also found that needle depth (1 mm or less versus more than 1 mm), treatment length and the device (electric pen or roller) made no significant difference to hair count. None of the three includes the 2026 trial in women, and a null result from 234 completers would weigh against the pooled effect.

Hair thickness shows why pooled numbers need reading carefully. Ahmed's six trials agreed on a small gain in diameter (SMD 0.34, with no heterogeneity), Pei also found one, and Xu's pooled estimate found none. Different trial sets, different answers. Hair count is the only outcome all three agree on, and it is the one with the widest disagreement between individual trials.

Derma roller vs clinic microneedling: what changes

A home roller differs from the trial device in depth, operator, sterility and how often it is used. Any of those could matter. None has been tested head to head in a hair loss trial.

	Dhurat 2013 and Kumar 2018	Typical home use
Needle length	1.5 mm	Chosen by the user, often much shorter than 1.5 mm
Who does it	Clinician, watching for redness or pinpoint bleeding	The user, on a scalp they cannot see
Scalp preparation	Shaved, povidone-iodine and saline	Up to the user
Frequency	Weekly, or weekly then fortnightly	Chosen by the user
Minoxidil timing	Skipped on the day, restarted 24 hours later	Up to the user
Monitoring	Hair counts, photographs, adverse events recorded	None

Two points follow. First, the depth argument cuts both ways. Ahmed's meta-analysis found no depth effect, which weakens the claim that only 1.5 mm works but also means no trial supports a particular home depth. Second, frequent home use has almost no trial behind it. No hair loss trial in the table above needled more often than weekly. A small randomised trial of a home-use microneedle device, used twice a week by 29 people for six months, found no statistically significant difference in hair count between groups (Sohng et al, J Cosmet Dermatol 2021). The case reports in the next section involved weekly and daily use.

Derma roller side effects for hair

In the trials, the reported side effects were mild pain during the procedure, redness, itching and short-lived swelling. The case reports and the dermatology society warnings describe what can go wrong outside a trial.

Source	What was reported	How often
Kumar 2018, 34 men	Mild pain and discomfort during the procedure	"Well tolerated by all patients"; no rate given
Adistri 2024, 36 men	Itching, mostly attributed to minoxidil; transient redness after needling	9 of 36 had any side effect (6 needling, 3 minoxidil alone); 1 case of transient redness
Ahmed 2025 meta-analysis, 631 people	Any adverse event	74 events with needling vs 59 without, "generally considered mild or self-limiting"
American Academy of Dermatology (general guidance, not hair-specific)	Infection or scarring if a home device pierces the skin; spreading warts, herpes and other viruses; skin colour change from pressing too hard	No rate
Xu et al, J Cosmet Dermatol 2026	Hair-shaft fragility and breakage after weekly 0.5 mm rolling	2 case reports
Aydemir et al, Skin Appendage Disord 2026	Basal cell carcinoma at the frontal hairline after 3 months of daily microneedling	1 case report

The 2026 fragility report is worth knowing about because it looks like treatment failure. Two patients, a man on finasteride and minoxidil and a woman on minoxidil, rolled weekly with a 500 µm roller. Both improved at first (the man for about nine months, the woman for about three), then thinned. Under an electron microscope, their hair shafts showed damaged cuticles, with lifted, separating or fragmented layers, and the authors attributed the thinning to broken, shortened hairs rather than shedding, while calling their proposed mechanisms hypothesis-generating. They describe it as a "biphasic course": initial improvement, then deterioration.

The skin cancer report is a single case. It cannot establish that microneedling caused the tumour, and the authors say further studies are needed. It is still the first published case of its kind, and the patient was needling daily, which is more often than any trial covered here.

A third 2026 case, of dissecting cellulitis of the scalp, followed a series of sessions of a different technique that pushes medication into the skin with a tattoo machine set to 1.2 mm (Oliveira et al, Cureus 2026). The patient had also been using testosterone and oral minoxidil. The authors raise repeated procedural microtrauma as a possible trigger and state that causality cannot be inferred from a single case.

The AAD says microneedling is not for anyone who heals slowly or poorly, has had a keloid scar, has a weakened immune system, is being treated for skin cancer in the area or is receiving radiation treatment, and that a dermatologist will wait if there is a recent tan, a skin infection, deep or pus-filled pimples, or isotretinoin taken within the past month (AAD, linked in the table above). The hair trials also excluded men with bleeding disorders or on anticoagulants (Kumar 2018, Leonik 2024) and men with a history of keloids (Kumar 2018, Adistri 2024).

Because nearly every derma roller hair regimen includes minoxidil, its own side effects apply too: scalp itching and irritation, more common on 5% than 2% (Olsen et al, J Am Acad Dermatol 2002), a temporary shed in the early weeks, and unwanted facial hair, spontaneously reported by 50 of 1,333 women (4%) across clinical trials that included placebo groups (Dawber and Rundegren, J Eur Acad Dermatol Venereol 2003). The rates and what they mean are in our guide to minoxidil side effects. The trials made patients wait 24 hours after needling before applying minoxidil. We found no human study measuring how much more minoxidil gets absorbed when it is applied straight onto freshly needled skin. In a small trial of a related technique, which pushes 0.5% minoxidil into the scalp through tattoo-machine needles, diastolic blood pressure fell after the procedure in the group given minoxidil rather than saline (24 patients in all), and the authors took this as a sign that the drug reached the bloodstream (Basilio et al, Arch Dermatol Res 2025).

Three claims that do not match their source

Three common derma roller hair claims each rest on something narrower than the claim.

"Derma rollers are FDA-cleared for hair growth." The FDA's 2020 guidance says a microneedling product generally meets the definition of a medical device when it claims to act beyond the dead outer layer of skin. "Treats alopecia (hair loss)" is one of the examples the FDA gives of a claim that makes a product a device (FDA guidance, November 2020). The FDA classifies microneedling devices "for aesthetic use" as Class II, which means they need 510(k) clearance before sale. The authorisation that created the category in 2018 was for a prescription pen that improves the appearance of facial acne scars (FDA De Novo DEN160029). A product's clearance for wrinkles or scars says nothing about hair.

"Microneedling alone regrows hair in mild cases." A 2026 paper in the Journal of Cosmetic Dermatology said exactly this. It was retracted in April 2026 after third parties found that "several cited references were found to be invalid or non-existent". The editors also noted "concerns regarding possible use of AI-generated content" (retraction notice). The authors disagree with the retraction. Its design could not have tested the claim anyway: the mild group got needling alone, the moderate and severe groups got needling plus drugs, and there was no untreated or randomised comparison.

"0.5 mm for home, 1.5 mm for real results." This is repeated as settled guidance, but the 2025 pooled analysis found no significant difference between depths of 1 mm or less and more than 1 mm, and the 2024 one favoured depths under 1 mm. The only large trial at the home-roller depth found no added benefit. The depth that works, if one does, has not been established.

Where a derma roller fits next to finasteride and minoxidil

Microneedling is an add-on to a drug, not a replacement for one, and the professional consensus that ranks it highest still puts it alongside the drugs rather than in their place. A 2025 Canadian Delphi consensus of 11 physicians, developed with L'Oréal Canada staff among the authors, listed microneedling among seven recommended interventions, alongside oral and topical finasteride, oral dutasteride, topical and oral minoxidil and PRP (Landells et al, J Cutan Med Surg 2025).

	Finasteride 1 mg	Minoxidil 5% topical	Derma roller or microneedling
FDA-approved for hair loss	Yes	Yes	No; devices are regulated for aesthetic use
Largest placebo- or sham-controlled evidence	1,553 men, two vertex trials	393 men, 48-week trial	No sham-controlled trial
What it does in trials	Keeps and regrows hair on counts	Regrows hair on counts	Adds to minoxidil in most small trials; nothing added in the largest
Main side effects	Sexual side effects: 3.8% vs 2.1% on placebo in year one, across all three trials (FDA label)	Itching, irritation, early shed, unwanted hair	Pain, redness, itching; case reports of hair breakage and skin cancer

The drug numbers and their timelines are on the finasteride vs minoxidil comparison and the minoxidil results page. Finasteride's own side-effect profile is covered in finasteride side effects. Finasteride and dutasteride are prescription-only in most countries and are not licensed for women who could become pregnant.

A fair reading of the evidence:

• Already on minoxidil and responding: the combination trials suggest needling may add a little to hair count, and possibly thickness. The largest trial found it added nothing. It is a small and uncertain gain, bought with regular scalp injury.
• On minoxidil with no response after the label checkpoint: a 2015 case series from the Dhurat group reported four patients with no new growth after 2 to 5 years of finasteride and minoxidil, some of whom had also had transplants or other treatments, and all four improved after needling was added (Indian J Dermatol 2015). Four patients with no control group is a hypothesis, not evidence. Other reasons minoxidil stalls are covered in minoxidil not working.
• Not on any drug: needling alone has the weakest evidence of all, and nothing suggests it slows the underlying loss.
• Just started minoxidil: adding a second treatment in the first few months makes it impossible to tell which one is doing what. The month-three checkpoint explains what that period can and cannot show.

Every trial in the table treated thinning hair that was still there, mostly vertex loss like that on the Norwood 3 vertex page. None suggests needling brings back a bare scalp. PRP is often sold alongside needling on the same logic, with similar caveats, set out in hair transplant vs PRP. The pattern is familiar from ketoconazole shampoo: a low-cost add-on with a plausible mechanism and a thin evidence base.

Frequently Asked Questions

How often should you use a derma roller for hair?

No trial has established an ideal frequency. The trials that found a benefit needled weekly, or weekly then fortnightly, and the largest trial found no difference between every two weeks and monthly. Few hair loss trials needled more often than weekly; one small trial of a home-use device used twice a week found no significant difference in hair count. A 2026 case report of skin cancer involved daily use.

What size derma roller is best for hair growth?

The two best-known positive trials used 1.5 mm, applied by clinicians. A 2025 meta-analysis found no significant difference in hair count between depths of 1 mm or less and more than 1 mm. The largest trial, at about 0.5 mm, found no benefit over minoxidil alone.

Can you apply minoxidil right after derma rolling?

In the trials, patients skipped minoxidil on the day of needling and restarted it 24 hours later. We found no human study measuring whether applying it straight after changes how much reaches the bloodstream, though a small trial of minoxidil pushed into the scalp through needles did record a fall in blood pressure. A prescriber can advise on timing.

Can a derma roller cause hair loss?

It can make hair look thinner. A 2026 report described two patients whose hair improved and then thinned, which the authors attributed to weekly rolling leaving the hair shafts fragile and broken. The AAD warns that an at-home device that pierces the skin can cause infection or scarring.

The bottom line

The derma roller hair evidence is real but narrow. It comes from small trials in which patients knew their treatment, often with deeper needles than most home rollers, almost always combined with minoxidil and mostly measured over 12 weeks. The best result is a modest gain in hair count, and possibly thickness, on top of the drug. The largest and most recent trial found no gain at all. The rare but documented harms, broken hair shafts and a skin cancer at a daily-needled hairline, followed use that went beyond what the trials tested: weekly rolling kept up for months, and daily needling.

A dermatologist can confirm whether the thinning is pattern hair loss, whether minoxidil or finasteride is the right base treatment, and whether in-office microneedling adds anything for that scalp. Taking your Norwood stage to the appointment keeps the conversation on the pattern rather than the product.